SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers



(b)  On January 4, 2017, Robert King, Ph.D., Senior Vice President, Product Development and Supply Chain, advised the Company of his resignation from his position as an officer of the Company to pursue other opportunities, effective as of January 18, 2017.







About SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Recent Trading Information

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) closed its last trading session down -0.20 at 10.60 with 480,888 shares trading hands.